Previous Close | 5,052.20 |
Open | 5,048.75 |
Bid | 5,036.90 x 0 |
Ask | 0.00 x 0 |
Day's Range | 4,985.00 - 5,105.35 |
52 Week Range | 2,495.05 - 5,512.65 |
Volume | 762,986 |
Avg. Volume | 1,317,009 |
Market Cap | 835.773B |
Beta (5Y Monthly) | 0.00 |
PE Ratio (TTM) | 54.49 |
EPS (TTM) | 92.43 |
Earnings Date | May 10, 2018 - May 14, 2018 |
Forward Dividend & Yield | 25.00 (0.49%) |
Ex-Dividend Date | Jul 13, 2020 |
1y Target Est | 2,587.45 |
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.